DOCSLIB.ORG

Patient Information Leaflet: Information for the User <Invented Name> 30

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patient Information Leaflet: Information for the User <Invented Name> 30 Patient Information Leaflet: Information for the user <Invented name> 30 mg/ml solution for injection ketorolac trometamol Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What <Invented name> is and what it is used for 2. What you need to know before you are given <Invented name> 3. How <Invented name> is given 4. Possible side effects 5. How to store <Invented name> 6. Contents of the pack and other information 1. What <Invented name> is and what it is used for <Invented name> contains an active substance called ketorolac trometamol and belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). Ketorolac is used in hospital, for short-term relief of moderate to severe pain after operations and in the case of acute kidney stone pain, in adults and adolescents ≥16 years. 2. What you need to know before you are given <Invented name> <Invented name> should not be used before or during surgery due to increased risk of bleeding. <Invented name> must not be given by epidural or intrathecal administration . Severe anaphylactic-like reactions have been observed in patients with a history of allergic reactions (symptoms of asthma, inflammation of the nasal mucosa or skin reactions) to the use of acetylsalicylic acid (e.g. aspirin) or other anti-inflammatory pain-relief drugs (NSAIDs). Do not use <Invented name>: if you are allergic to ketorolac or any of the other ingredients of this medicine (listed in section 6). in combination with other anti-inflammatory pain relief drugs (NSAIDs) or acetylsalicylic acid if you have or have had any problems with your stomach or gut, like an ulcer or bleeding if you have severe problems with your liver or heart if you have moderate to severe problems with your kidneys, or are at risk for kidney failure due to dehydration if you are pregnant and in the final trimester (have been pregnant for more than six months) during labour or delivery if you are breast-feeding if you have, or have had bleeding in your brain or other bleeding disorders if you are taking oxpentifylline (a medicine used to improve blood circulation) . Warnings and precautions Medicines like <Invented name> may be associated with a slight increase in the risk of heart attack or stroke, especially in high doses or when used in the long term. It is therefore important that you are not given <Invented name> for longer than recommended and you do not use more than the recommended dose. If you have heart problems, have had a stroke or believe that you may be at risk of such problems (for example, if you have high blood pressure, diabetes, high cholesterol or if you smoke), you should ask your doctor or nurse for advice before starting treatment. Talk to your doctor before you are given <Invented name> and tell your doctor if: you have problems with your kidney, liver or heart have high blood pressure and/or problems with the blood vessels (arteries) in your body you have ischaemic heart disease also called coronary artery disease you have a very low blood volume (hypovolemia) or if you are dehydrated you are taking other non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief or to reduce fever (e.g. ibuprofen or aspirin) you may be pregnant or are planning to have a baby or undergoing testing for infertility you have a coagulation disorder you have chickenpox you have systemic lupus erythematosus, an autoimmune disease you suffer from ulcerative colitis or Crohns disease you have a family history of asthma, nasal polyps (lumps in your nose), long-term swelling of the sinus (chronic sinusitis) or hives you have a history of hypersensitivity to acetylsalicylic acid, other NSAIDs, or ketorolac If you experience gastrointestinal bleeding or ulceration, signs of liver disease or other manifestations such as rash, stop the treatment with this medicine. Severe skin and soft-tissue reactions have been reported in very rare cases when using a NSAID. Stop the treatment with <Invented name> and contact your doctor if you develop a severe skin and soft-tissue reactions. Allergic or anaphylactoid reactions (anaphylactoid reaction is a severe allergic reaction which causes severe problems breathing or dizziness), have been reported in patients with a history of hypersensitivity to acetylsalicylic acid, other NSAIDs, or ketorolac. However, these reactions may also occur in patients without a history of allergy to these drugs. <Invented name> is not recommended if you are undergoing dialysis. Children and adolescents Safety and efficacy in children and adolescents under 16 years of age has not been assessed. Injection of <Invented name> is not recommended for children under16 years of age. Elderly If you are elderly you are more likely to suffer problems, especially bleeding and perforation in the digestive tract. Other medicines and <Invented name> Tell your doctor if you are using, have recently used or might use any other medicines. Tell your doctor if you are using any of the following types of medicines: Blood-thinning agents (antiplatelet drugs and anti-coagulants; warfarin, heparin and dextrans) Diuretics (water tablets) Beta-blockers (heart medicine) Methotrexate (amongst other things for psoriasis, arthritis, other autoimmune diseases, cancer) Cyclosporine (immunosuppressive drug) Lithium (mood stabiliser) ACE inhibitors/Angiotensin-II_antagonists (heart medicine/for high blood pressure) Oxpentoxifylline (for claudicatio intermittens) Alcohol SSRIs (preparations to treat depression/anxiety) Other NSAIDs such as acetylsalicylic acid (ASA), celecoxib, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, rofecoxib, sulindac, tenoxicam, tiaprofenic acid, tolmetin, or valdecoxib (NOT a complete list) Corticosteroids Opioid analgesics Tacrolimus (immunosuppressive drug) Probenecid (a medicine used for treating problems caused by too much uric acid in your body (e.g. gout, gouty arthritis) Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. <Invented name> can make it more difficult to become pregnant. Tell your doctor if you are planning to become pregnant or if you have difficulties becoming pregnant. As with other drugs containing aspirin or other NSAIDs, you must inform your doctor before using <Invented name> if you are pregnant. Do not use <Invented name> if you have been pregnant for more than 6 months. Ketorolac passes into breast milk and the breast-feeding child may be affected. <Invented name> should not therefore be used when breast-feeding. Driving and using machines <Invented name> can affect the ability to drive and use machines, as dizziness, drowsiness and headaches can occur. <Invented name> must not therefore be used if you are driving or using machines. <Invented name> contains ethanol and sodium This medicinal product contains small amounts of ethanol (alcohol), less than 100 mg per dose. This medicinal product contains less than 1 mmol sodium (23 mg) per ampoule, that is to say essentially ‘sodium-free’. 3. How <Invented name> is given <Invented name> is administered by healthcare professionals and the treatment should only be started in hospital. <Invented name> is given by injection into a muscle (intramuscularly) or into a blood vessel (into a vein, also known as intravenously). The <Invented name> dose will vary from one patient to another. Your doctor will decide a suitable dose for you. <Invented name> If you have any further questions on the use of this medicine, ask your doctor or nurse. 4. Possible side effects Like all medicines, <Invented name> can cause side effects, although not everybody gets them. Common (≥1/100 to <1/10) headache, drowsiness, sweating, dizziness, swelling at the injection site (oedema), nausea, dyspepsia (indigestion), abdominal pain, diarrhoea. Uncommon (≥1/1,000 to <1/100) inflammation of the lining of the stomach (gastritis), gastrointestinal ulceration, bloody stools (melaena), intestinal gas (flatulence), constipation, rectal bleeding, inflammation of the mouth (stomatitis), vomiting, dry mouth, abnormal taste, tingling of the skin, depression, sleeping disorder (insomnia), nervousness, intense feeling of well-being (euphoria), inability to concentrate, abnormal thoughts, elevated liver enzymes (ASAT) abnormal vision, muscle pain, increased frequency of urination, problems passing water (urine retention), small amounts of urine, shortness of breath, asthma, nosebleeds, itching, flushing, rash, blood spots on the skin (purpura), weakness (asthenia), thirst, pale skin, Rare (≥1/10,000 to <1/1,000) heart failure low amount of platelets, low or high blood pressure, bleeding after surgery, convulsions (seizures), muscle spasm, abnormal dreams, hallucinations, hearing loss, acute kidney failure, flank pain with or without blood in the urine) and/or increased urea in the blood (azotemia), fluid accumulation in lungs (pulmonary oedema), serious allergic reaction (anaphylactic reactions),
Load more

Recommended publications
  • Nsaids: Dare to Compare 1997
    NSAIDs TheRxFiles DARE TO COMPARE Produced by the Community Drug Utilization Program, a Saskatoon District Health/St. Paul's Hospital program July 1997 funded by Saskatchewan Health. For more information check v our website www.sdh.sk.ca/RxFiles or, contact Loren Regier C/O Pharmacy Department, Saskatoon City Hospital, 701 Queen St. Saskatoon, SK S7K 0M7, Ph (306)655-8506, Fax (306)655-8804; Email [email protected] We have come a long way from the days of willow Highlights bark. Today salicylates and non-steroidal anti- • All NSAIDs have similar efficacy and side inflammatory drugs (NSAIDs) comprise one of the effect profiles largest and most commonly prescribed groups of • In low risk patients, Ibuprofen and naproxen drugs worldwide.1 In Saskatchewan, over 20 may be first choice agents because they are different agents are available, accounting for more effective, well tolerated and inexpensive than 300,000 prescriptions and over $7 million in • Acetaminophen is the recommended first line sales each year (Saskatchewan Health-Drug Plan agent for osteoarthritis data 1996). Despite the wide selection, NSAIDs • are more alike than different. Although they do Misoprostol is the only approved agent for differ in chemical structure, pharmacokinetics, and prophylaxis of NSAID-induced ulcers and is to some degree pharmacodynamics, they share recommended in high risk patients if NSAIDS similar mechanisms of action, efficacy, and adverse cannot be avoided. effects. week or more to become established. For this EFFICACY reason, an adequate trial of 1-2 weeks should be NSAIDs work by inhibiting cyclooxygenase (COX) allowed before increasing the dose or changing to and subsequent prostaglandin synthesis as well as another NSAID.
    [Show full text]
  • Diclofenac Sodium Enteric-Coated Tablets) Tablets of 75 Mg Rx Only Prescribing Information
    ® Voltaren (diclofenac sodium enteric-coated tablets) Tablets of 75 mg Rx only Prescribing Information Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS.) • Voltaren® (diclofenac sodium enteric-coated tablets) is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS.) DESCRIPTION Voltaren® (diclofenac sodium enteric-coated tablets) is a benzene-acetic acid derivative. Voltaren is available as delayed-release (enteric-coated) tablets of 75 mg (light pink) for oral administration. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.14. Its molecular formula is C14H10Cl2NNaO2, and it has the following structural formula The inactive ingredients in Voltaren include: hydroxypropyl methylcellulose, iron oxide, lactose, magnesium stearate, methacrylic acid copolymer, microcrystalline cellulose, polyethylene glycol, povidone, propylene glycol, sodium hydroxide, sodium starch glycolate, talc, titanium dioxide. CLINICAL PHARMACOLOGY Pharmacodynamics Voltaren® (diclofenac sodium enteric-coated tablets) is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Voltaren, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.
    [Show full text]
  • (Ketorolac Tromethamine Tablets) Rx Only WARNING TORADOL
    TORADOL ORAL (ketorolac tromethamine tablets) Rx only WARNING TORADOLORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOLORAL and ketorolac tromethamine should not exceed 5 days. TORADOLORAL is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of TORADOLORAL beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES). TORADOL is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
    [Show full text]
  • Arthritis Treatment Comparison Arthritis Treatment Comparison
    ARTHRITIS TREATMENT COMPARISON ARTHRITIS TREATMENT COMPARISON GENERIC OA of (BRAND) HOW SUPPLIED AS GA JIA JRA OA Knee PsA RA CHELATING AGENTS Penicillamine Cap: 250mg ✓ (Cuprimine) Penicillamine Tab: 250mg ✓ (Depen) CYCLIC POLYPEPTIDE IMMUNOSUPPRESSANTS Cyclosporine Cap: 25mg, 100mg; ✓ (Gengraf, Neoral) Sol: 100mg/mL CYCLOOXYGENASE-2 INHIBITORS Celecoxib Cap: 50mg, 100mg, ✓ ✓ ✓ ✓ (Celebrex) 200mg, 400mg DIHYDROFOLIC ACID REDUCTASE INHIBITORS Methotrexate Inj: 25mg/mL; ✓ ✓ Tab: 2.5mg Methotrexate Tab: 5mg, 7.5mg, ✓ ✓ (Trexall) 10mg, 15mg INTERLEUKIN RECEPTOR ANTAGONISTS Anakinra Inj: 100mg/0.67mL ✓ (Kineret) Tocilizumab Inj: 20mg/mL, ✓ ✓ (Actemra) 162mg/0.9mL GOLD COMPOUNDS Auranofin Cap: 3mg ✓ (Ridaura) Gold sodium thiomalate Inj: 50mg/mL ✓ ✓ (Myochrysine) HYALURONAN AND DERIVATIVES Hyaluronan Inj: 30mg/2mL ✓ (Orthovisc) Sodium hyaluronate Inj: 1% ✓ (Euflexxa) Sodium hyaluronate Inj: 10mg/mL ✓ (Hyalgan) Sodium hyaluronate Inj: 2.5mL ✓ (Supartz) HYLAN POLYMERS Hylan G-F 20 Inj: 8mg/mL ✓ (Synvisc, Synvisc One) KINASE INHIBITORS Tofacitinib Tab: 5mg ✓ (Xeljanz) MONOCLONAL ANTIBODIES Ustekinumab Inj: 45mg/0.5mL, ✓ (Stelara) 90mg/mL MONOCLONAL ANTIBODIES/CD20-BLOCKERS Rituximab Inj: 100mg/10mL, ✓ (Rituxan) 500mg/50mL (Continued) ARTHRITIS TREATMENT COMPARISON GENERIC OA of (BRAND) HOW SUPPLIED AS GA JIA JRA OA Knee PsA RA MONOCLONAL ANTIBODIES/TNF-BLOCKERS Adalimumab Inj: 20mg/0.4mL, ✓ ✓ ✓ ✓ (Humira) 40mg/0.8mL Golimumab Inj: 50mg/0.5mL, ✓ ✓ ✓ (Simponi) 100mg/mL Infliximab Inj: 100mg ✓ ✓ ✓ (Remicade) NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    [Show full text]
  • Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (See the end of this Medication Guide for a list of prescription NSAID medicines.) What is the most important information I should know about medicines called Non-Steroidal Anti- Inflammatory Drugs (NSAIDs)? NSAID medicines may increase the chance of a heart attack or stroke that can lead to death. This chance increases: • with longer use of NSAID medicines • in people who have heart disease NSAID medicines should never be used right before or after a heart surgery called a “coronary artery bypass graft (CABG).” NSAID medicines can cause ulcers and bleeding in the stomach and intestines at any time during treatment. Ulcers and bleeding: can happen without warning symptoms may cause death The chance of a person getting an ulcer or bleeding increases with: ▪ taking medicines called "corticosteroids” and “anticoagulants” ▪ longer use ▪ smoking ▪ drinking alcohol ▪ older age ▪ having poor health NSAID medicines should only be used: • exactly as prescribed • at the lowest dose possible for your treatment • for the shortest time needed What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? NSAID medicines are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as: different types of arthritis menstrual cramps and other types of short-term pain Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)? Do not take an NSAID medicine: • if you had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAID medicine • for pain right before or after heart bypass surgery Tell your healthcare provider: • about all of your medical conditions.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH NOVO–KETOROLAC (ketorolac tromethamine) 10 mg Tablets NSAID Analgesic Agent Novopharm Limited Date of Revision: Toronto, Canada August 02, 2007 Control Number 112565 PRODUCT MONOGRAPH NOVO–KETOROLAC (ketorolac tromethamine) 10 mg Tablets THERAPEUTIC CLASSIFICATION NSAID Analgesic Agent ACTION AND CLINICAL PHARMACOLOGY NOVO-KETOROLAC (ketorolac tromethamine) is a non-steroidal anti-inflammatory drug (NSAID) that has analgesic activity. It is considered to be a peripherally acting analgesic. It is thought to inhibit the cyclo-oxygenase enzyme system, thereby inhibiting the synthesis of prostaglandins. At analgesic doses it has minimal anti-inflammatory and antipyretic activity. The peak analgesic effect occurs at 2 to 3 hours post-dosing with no evidence of a statistically significant difference over the recommended dosage range. The greatest difference between large and small doses of administered ketorolac is in the duration of analgesia. Following oral administration, ketorolac tromethamine is rapidly and completely absorbed, and pharmacokinetics are linear following single and multiple dosing. Steady state plasma levels are achieved after one day of q.i.d. dosing. - 2 - Peak plasma concentrations of 0.7 to 1.1 µg/mL occurred at 44 minutes following a single oral dose of 10 mg. The terminal plasma elimination half-life ranged between 2.4 and 9 hours in healthy adults, while in the elderly subjects (mean age: 72 years) it ranged between 4.3 and 7.6 hours. A high fat meal decreased the rate but not the extent of absorption of oral ketorolac tromethamine, while antacid had no effect. In renally impaired patients there is a reduction in clearance and an increase in the terminal half- life of ketorolac tromethamine (See Table 1).
    [Show full text]
  • DAYPRO ALTA™ (Oxaprozin Potassium) 600Mg Tablets Cardiovascular Risk • Nsaids May Cause an Increased Risk of Serious Cardiov
    DAYPRO ALTA™ (oxaprozin potassium) 600mg tablets Cardiovascular Risk NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patient’s with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS). Daypro ALTA is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk NSAID’s cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). DESCRIPTION DAYPRO ALTA (oxaprozin potassium tablets) is a member of the propionic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each blue, capsule-shaped tablet contains oxaprozin potassium (678mg equivalent to 600mg of oxaprozin) for oral administration. The chemical name for oxaprozin potassium is 4,5-diphenyl-2-oxazolepropionic acid, potassium salt. Its empirical formula is C18H14NO3K, and molecular weight is 331. Oxaprozin potassium is a white to off white powder with a melting point of 215°C. It is slightly soluble in alcohol and very soluble in water. The PK in water is 9.7. It has the following structural formula: Inactive ingredients in DAYPRO ALTA tablets include microcrystalline cellulose, hydroxypropyl methylcellulose, pregelatinized corn starch, stearic acid, colloidal silicon dioxide, polyethylene glycol, titanium dioxide, FD&C Blue #1 Aluminum Lake, and pharmaceutical glaze.
    [Show full text]
  • Of 20 PRODUCT MONOGRAPH FLURBIPROFEN Flurbiprofen Tablets BP 50 Mg and 100 Mg Anti-Inflammatory, Analgesic Agent AA PHARM
    PRODUCT MONOGRAPH FLURBIPROFEN Flurbiprofen Tablets BP 50 mg and 100 mg Anti-inflammatory, analgesic agent AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road, Unit #1 April 16, 1991 Vaughan, Ontario L4K 4N7 DATE OF REVISION: February 7, 2019 Submission Control No. 223098 Page 1 of 20 PRODUCT MONOGRAPH NAME OF DRUG FLURBIPROFEN Flurbiprofen Tablets BP 50 mg and 100 mg PHARMACOLOGICAL CLASSIFICATION Anti-inflammatory, analgesic agent ACTIONS AND CLINICAL PHARMACOLOGY FLURBIPROFEN (flurbiprofen), a phenylalkanoic acid derivative, is a non-steroidal anti- inflammatory agent which also possesses analgesic and antipyretic activities. Its mode of action, like that of other non-steroidal anti-inflammatory agents, is not known. However, its therapeutic action is not due to pituitary adrenal stimulation. Flurbiprofen is an inhibitor of prostaglandin synthesis. The resulting decrease in prostaglandin synthesis may partially explain the drug's anti-inflammatory effect at the cellular level. Pharmacokinetics: Flurbiprofen is well absorbed after oral administration, reaching peak blood levels in approximately 1.5 hours (range 0.5 to 4 hours). Administration of flurbiprofen with food does not alter total drug availability but delays absorption. Excretion of flurbiprofen is virtually complete 24 hours after the last dose. The elimination half-life is 5.7 hours with 90% of the half-life values from 3-9 hours. There is no evidence of drug accumulation and flurbiprofen does not induce enzymes that alter its metabolism. Flurbiprofen is rapidly metabolized and excreted in the urine as free and unaltered intact drug (20-25%) and hydroxylated metabolites (60-80%). In animal models of inflammation the metabolites showed no activity.
    [Show full text]
  • Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti- Inflammatory Drugs: a Systematic Review
    J Pharm Pharm Sci (www.cspsCanada.org) 21, 48s – 73s, 2018 Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti- Inflammatory Drugs: A Systematic Review Zuhair Alqahtani and Fakhreddin Jamali Faculty of Pharmacy and Pharmaceutical Science, University of Alberta, Edmonton, Alberta, Canada. Received, March 16, 2018; Revised, March 30, 2018; Accepted, April 25, 2018; Published, April 27, 2018. ABSTRACT - Purpose: Concomitant use of some non-Aspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) reduces the extent of platelet aggregation of Aspirin (acetylsalicylic acid). This is while many observational studies and clinical trials suggest that Aspirin reduces cardiovascular (CV) risk attributed to the use of NANSAIDs. Thus, the therapeutic outcome of the interaction needs to be assessed. Methods: We searched various databases up to October 2017 for molecular interaction studies between the drugs and long-term clinical outcomes based on randomized clinical trials and epidemiological observations that reported the effect estimates of CV risks (OR, RR or HR; 95% CI) of the interacting drugs alone or in combinations. Comparisons were made between outcomes after Aspirin alone, NANSAIDs alone and Aspirin with naproxen, ibuprofen, celecoxib, meloxicam, diclofenac or rofecoxib. Results: In total, 32 eligible studies (20 molecular interactions studies and 12 observational trials) were found. Conflicting in vitro/in vivo/ex vivo platelet aggregation data were found for ibuprofen, naproxen and celecoxib. Nevertheless, for naproxen, the interaction at the aggregation level did not amount to a loss of cardioprotective effects of Aspirin. Similarly, for ibuprofen, the results overwhelmingly suggest no negative clinical CV outcomes following the combination therapy. Meloxicam and rofecoxib neither interacted with Aspirin at the level of platelet aggregation nor altered clinical outcomes.
    [Show full text]
  • Ketorolac Tromethamine Injection
    ! • unusual weight gain Ketorolac Tromethamine Injection, USP Rx only Table 1: Table of Approximate Average Pharmacokinetic Parameters (Mean ± SD) IV-Administration: In normal subjects (n=37), the total clearance of 30 mg IV-administered ketorolac tromethamine was Anaphylactoid Reactions 0.030 (0.017-0.051) L/h/kg. The terminal half-life was 5.6 (4.0-7.9) hours. (See Kinetics in Special Populations for use of • skin rash or blisters with fever FOR IV/IM USE (15 mg/mL and 30 mg/mL) Following Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to ketorolac tromethamine. Oral† Intramuscular* Intravenous Bolus‡ IV dosing of ketorolac tromethamine in pediatric patients.) Ketorolac tromethamine should not be given to patients with the aspirin triad. This symptom complex typically occurs in • swelling of the arms and legs, hands and feet FOR IM USE ONLY (60 mg/2 mL (30 mg/mL) asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm Pharmacokinetic CLINICAL STUDIES These are not all the side effects with NSAID medicines. Talk to your healthcare provider or Parameters 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS – Pre-existing Asthma). Emergency WARNING (units) Adult Patients help should be sought in cases where an anaphylactoid reaction occurs. pharmacist for more information about NSAID medicines. Bioavailability 100% In a postoperative study, where all patients received morphine by a PCA device, patients treated with ketorolac tromethamine IV Cardiovascular Effects Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days (extent) in adults) management of moderately severe acute pain that requires analgesia at the opioid level.
    [Show full text]
  • Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac Or Ketorolac
    molecules Article Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac Héctor Isaac Rocha-González 1 , María Elena Sánchez-Mendoza 1, Leticia Cruz-Antonio 2, Francisco Javier Flores-Murrieta 1,3, Xochilt Itzel Cornelio-Huerta 1 and Jesús Arrieta 1,* 1 Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Colonia Casco de Santo Tomás, Miguel Hidalgo, Ciudad de México 11340, Mexico; [email protected] (H.I.R.-G.); [email protected] (M.E.S.-M.); fjfl[email protected] (F.J.F.-M.); [email protected] (X.I.C.-H.) 2 Facultad de Estudios Superiores Zaragoza, UNAM, Av. Guelatao No. 66, Colonia Ejército de Oriente, Iztapalapa, Ciudad de México 09230, Mexico; [email protected] 3 Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosió Villegas, Secretaría de Salud, Ciudad de México 14080, Mexico * Correspondence: [email protected]; Tel.: +55-5729-6300 (ext. 62740); Fax: +55-5622-5329 Received: 13 October 2020; Accepted: 31 October 2020; Published: 3 November 2020 Abstract: Although nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the main types of drugs used to treat pain, they have several adverse effects, and such effects can be reduced by combining two analgesic drugs. The aim of this study was to evaluate the nociceptive activity of methyleugenol combined with either diclofenac or ketorolac, and determine certain parameters of pharmacokinetics. For the isobolographic analysis, the experimental effective dose 30 (ED30) was calculated for the drugs applied individually. With these effective doses, the peak plasma concentration (Cmax) was found and the other parameters of pharmacokinetics were established.
    [Show full text]
  • 2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report Date: September 2003 Update 2 Report Date: May 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Mark Helfand, MD, MPH Kim Peterson, MS Tracy Dana, MLS Carol Roberts, BS Produced by Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically(see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 3 Drug Effectiveness Review Project TABLE OF CONTENTS Evidence Table 1. Systematic reviews…………………………………………………………………3 Evidence Table 2. Randomized-controlled trials………………………………………………………9 Evidence Table 3.
    [Show full text]